TNF and colitis: In the Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) trials, tofacitinib induced remission more often than placebo in patients with moderate-to-severe UC who failed initial conventional therapy or anti-TNF therapy.